Clinical Trial Update: Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study [Phase 4]

View source ↗

Summary

A Phase 4 pilot study is evaluating a modified starting dosage of avatrombopag for immune thrombocytopenia, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• DOPTELET (avatrombopag)

Snippet

Sponsor: Al-Mustansiriyah University | Conditions: ITP - Immune Thrombocytopenia | Phase 4 | Status: RECRUITING